Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
New mRNA vaccine approach protects monkeys from HIV-like virus.
An experimental approach to protect HIV-fighting T cells has been cleared for its first human trial.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
Results from randomized clinical trials of the antiviral drug continue to show mixed results.
Cancer-fighting T cells led to complete or partial tumor remission in at least 25% of lung cancer patients.
Drugs used for decades to treat malaria may help people with the new coronavirus, but clinical trials are needed.
The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.
Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
New initiative will help health care providers navigate the process of submitting expanded access requests.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.